Cannara Biotech (CNBTF) Stock Price, News & Analysis

Company Overview

Cannara Biotech Ltd. (OTCMKTS:CNBTF) is a Canadian licensed producer of medical and adult-use cannabis, headquartered in Winnipeg, Manitoba. Founded in 2012, the company operates under its Health Canada licence to cultivate, process and sell cannabis products. Over the years, Cannara Biotech has established itself as a vertically integrated operation, overseeing every step from seed to sale within its state-of-the-art greenhouse facility.

The company’s core business activities center on the cultivation of cannabis flower and the production of derivative products such as oils, extracts and tinctures. Utilizing advanced greenhouse technology, Cannara Biotech maintains strict environmental controls to ensure consistency in cannabinoid profiles and terpene expression. In addition to its dried flower offerings, the company has invested in post-harvest processes, including extraction and formulation capabilities, allowing it to supply a range of dosage forms tailored to both medical patients and adult-use consumers.

While Cannara Biotech primarily serves the Canadian market, it has explored strategic partnerships to expand its footprint and to support research collaborations in emerging medical applications of cannabis. The company’s facility in West St. Paul, Manitoba, benefits from close proximity to key distribution channels, enabling efficient product delivery to provincial regulators and private retail outlets. This regional presence also positions Cannara Biotech to respond quickly to changes in regulatory requirements and consumer demand across the country.

Led by a management team with backgrounds in agronomy, pharmaceutical sciences and regulatory compliance, Cannara Biotech emphasizes quality assurance and Good Production Practices (GPP). The company’s executive leadership has guided Cannara Biotech through licensing milestones and facility upgrades, underscoring its commitment to meeting stringent industry standards. As the cannabis sector continues to evolve, Cannara Biotech aims to leverage its cultivation expertise and processing capabilities to grow market share and deliver consistent, high-quality products.

Key Stats

• Today's Range: $1.32 to $1.34
• 50-Day Range: $0.84 to $1.09
• 52-Week Range: $0.08 to $0.20
• Volume: 17,636 shs
• Average Volume: 33,127 shs
• Market Capitalization: N/A
• P/E Ratio: N/A
• Dividend Yield: N/A
• Price Target: N/A
• Consensus Rating: N/A

CNBTF Stock Analysis - Frequently Asked Questions

How have CNBTF shares performed this year?

Cannara Biotech's stock was trading at $0.5145 on January 1st, 2025. Since then, CNBTF shares have increased by 149.4% and is now trading at $1.2830.

How do I buy shares of Cannara Biotech?

Shares of CNBTF stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.

Industry, Sector and Symbol

• Stock Exchange: OTCMKTS
• Sector: N/A
• Industry: N/A
• Sub-Industry: N/A
• Current Symbol: OTCMKTS:CNBTF
• CIK: N/A
• Web: cannara.ca
• Phone: N/A
• Fax: N/A
• Employees: 13
• Year Founded: N/A

Profitability

• EPS (Trailing Twelve Months): N/A
• Trailing P/E Ratio: N/A
• Forward P/E Ratio: N/A
• P/E Growth: N/A
• Net Income: N/A
• Net Margins: N/A
• Pretax Margin: N/A
• Return on Equity: N/A
• Return on Assets: N/A

Debt

• Debt-to-Equity Ratio: N/A
• Current Ratio: N/A
• Quick Ratio: N/A

Sales & Book Value

• Annual Sales: N/A
• Price / Sales: N/A
• Cash Flow: N/A
• Price / Cash Flow: N/A
• Book Value: N/A
• Price / Book: N/A

Miscellaneous

• Outstanding Shares: N/A
• Free Float: N/A
• Market Cap: N/A
• Optionable: Not Optionable
• Beta: N/A